查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2037266

全球黏多醣症治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Mucopolysaccharidosis Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球黏多醣症治療市場預計將從2025年的53.3億美元成長至2034年的137.2億美元，2026年至2034年的複合年成長率（CAGR）為11.07%。隨著人們對罕見遺傳疾病的認知不斷提高，以及生物技術的進步使得更有針對性的治療方法成為可能，該市場正蓬勃發展。黏多醣症（MPS）是指一組由特定酵素缺乏引起的遺傳性代謝紊亂，這些酵素是分解Glico所必需的。這些疾病會導致進行性的身體和神經系統併發症，需要長期、專業的醫療照護。對早期診斷和早期療育的日益重視顯著改善了患者的預後，從而推動了對有效治療方法的需求。

這一成長得益於酵素替代療法 (ERT) 和基因療法研究的進展，以及對孤兒藥研發投入的增加。製藥公司正積極研發針對 MPS 根本病因的治療方法，而不僅僅是控制症狀。監管激勵措施，例如加速核准和資助罕見疾病研究，正在刺激該領域的創新。此外，診斷技術的進步，包括基因檢測和新生兒篩檢項目，使得早期發現和治療成為可能。患者權益倡導組織和全球宣傳宣傳活動在擴大治療覆蓋範圍方面也發揮著至關重要的作用。

未來前景極為光明，目前的研究重點正集中在基因編輯技術和個人化醫療領域。更有效、創傷更小的治療方法的發展將提高患者的用藥依從性和生活品質。在新興市場，隨著醫療基礎設施的完善和專科治療覆蓋範圍的擴大，預計治療方法將逐步普及。隨著我們對罕見疾病的科學認知不斷加深，黏多醣症治療市場可望迎來持續且變革性的成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面而實用的見解。每份報告都包含幾個關鍵組成部分，旨在讓您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業的市場定位、產品系列、策略舉措和財務表現進行了詳細評估。這為深入了解競爭動態和主要參與者所採取的策略提供了寶貴的見解。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球黏多醣症症治療市場：依治療方法分類

  • 市場分析、洞察與預測
  • 酵素替代療法（ERT）
  • 其他

第5章 全球黏多醣症症治療市場：依疾病類型分類

  • 市場分析、洞察與預測
  • 黏多醣症1型
  • Ⅱ型黏多醣症
  • 黏多醣症IVA型
  • VI型黏多醣症
  • 其他

第6章：全球黏多醣症症治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 靜脈
  • 腦室內腔（ICV）

第7章 全球黏多醣症症治療市場：依最終使用者分類

  • 市場分析、洞察與預測
  • 醫院
  • 專科診所
  • 其他

第8章 全球黏多醣症治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Denali Therapeutics
    • ArmaGen
    • REGENXBIO Inc
    • Sangamo Therapeutics
    • BioMarin
    • Lysogene
    • Abeona Therapeutics Inc
    • Ultragenyx Pharmaceutical
    • Genzyme Corporation
簡介目錄
Product Code: VMR11212371

The global mucopolysaccharidosis treatment market size is expected to reach USD 13.72 Billion in 2034 from USD 5.33 Billion in 2025, growing at a CAGR of 11.07 during 2026-2034.This market is gaining momentum as awareness of rare genetic disorders increases and advancements in biotechnology enable more targeted treatment approaches. Mucopolysaccharidosis (MPS) refers to a group of inherited metabolic disorders caused by the deficiency of specific enzymes required to break down glycosaminoglycans. These conditions lead to progressive physical and neurological complications, requiring long-term and specialized medical care. Increasing focus on early diagnosis and intervention is significantly improving patient outcomes and driving demand for effective treatment options.

Growth is supported by advancements in enzyme replacement therapy (ERT), gene therapy research, and increased investment in orphan drug development. Pharmaceutical companies are actively developing therapies that address the underlying causes of MPS rather than just managing symptoms. Regulatory incentives, including fast-track approvals and funding for rare disease research, are encouraging innovation in this space. Additionally, improvements in diagnostic techniques, including genetic testing and newborn screening programs, are enabling earlier detection and treatment initiation. Patient advocacy groups and global awareness campaigns are also playing a crucial role in expanding access to treatment.

Future prospects indicate strong potential, with ongoing research focused on gene editing technologies and personalized medicine. The development of more effective and less invasive therapies will enhance patient compliance and quality of life. Emerging markets are expected to see gradual adoption as healthcare infrastructure improves and access to specialized treatments increases. As scientific understanding of rare diseases continues to evolve, the mucopolysaccharidosis treatment market is poised for sustained and transformative growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment

  • Enzyme Replacement Therapy (ERT)
  • Others

By Disease Type

  • Mucopolysaccharidosis Type I
  • Mucopolysaccharidosis Type II
  • Mucopolysaccharidosis Type IV A
  • Mucopolysaccharidosis Type VI
  • Others

By Route of Administration

  • Intravenous
  • Intracerebroventricular (ICV)

By End User

  • Hospitals
  • Specialty Clinics
  • Others

COMPANIES PROFILED

  • Shire (Takeda Pharmaceutical Company Limited), Denali Therapeutics, ArmaGen, REGENXBIO Inc., Sangamo Therapeutics, BioMarin, Lysogene, Abeona Therapeutics Inc., Ultragenyx Pharmaceutical, Genzyme Corporation

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment
  • 4.2. Enzyme Replacement Therapy (ERT) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Disease Type
  • 5.2. Mucopolysaccharidosis Type I Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Mucopolysaccharidosis Type II Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Mucopolysaccharidosis Type IV A Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Mucopolysaccharidosis Type VI Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Intracerebroventricular (ICV) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT MARKET: BY END USER 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End User
  • 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Treatment
    • 8.2.2 By Disease Type
    • 8.2.3 By Route Of Administration
    • 8.2.4 By End User
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Treatment
    • 8.3.2 By Disease Type
    • 8.3.3 By Route Of Administration
    • 8.3.4 By End User
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Treatment
    • 8.4.2 By Disease Type
    • 8.4.3 By Route Of Administration
    • 8.4.4 By End User
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Treatment
    • 8.5.2 By Disease Type
    • 8.5.3 By Route Of Administration
    • 8.5.4 By End User
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Treatment
    • 8.6.2 By Disease Type
    • 8.6.3 By Route Of Administration
    • 8.6.4 By End User
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Denali Therapeutics
    • 10.2.2 ArmaGen
    • 10.2.3 REGENXBIO Inc
    • 10.2.4 Sangamo Therapeutics
    • 10.2.5 BioMarin
    • 10.2.6 Lysogene
    • 10.2.7 Abeona Therapeutics Inc
    • 10.2.8 Ultragenyx Pharmaceutical
    • 10.2.9 Genzyme Corporation